A Randomised, Double-Blind, Multicentre Dose-Finding Phase IIb Study for Up to 8 Weeks' Treatment With AZD0865 25, 50, 75 Mg and Esomeprazole 40 Mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.

Trial Profile

A Randomised, Double-Blind, Multicentre Dose-Finding Phase IIb Study for Up to 8 Weeks' Treatment With AZD0865 25, 50, 75 Mg and Esomeprazole 40 Mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2010

At a glance

  • Drugs AZD 0865; Esomeprazole
  • Indications Erosive oesophagitis; Gastro-oesophageal reflux; Heartburn; Reflux oesophagitis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Mar 2010 Patient segment added, and title amended to treat erosive-oesophagitis.
    • 25 Aug 2009 Actual initiation date (May 2004) and actual end date (Mar 2005) added as reported by ClinicalTrials.gov
    • 11 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top